Loading clinical trials...

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT03533673

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

Open-label, ascending dose trial of ACTUS-101 administered intravenously.

Lead sponsor: AskBio Inc•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

AskBio Inc

Related studies

A Global Prospective Observational Registry of Patients With Pompe Disease

NCT06121011 · Pompe Disease

Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology

NCT07136844 · Neuromuscular Diseases, Obesity (Disorder), and more

Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

NCT01665326 · Pompe Disease

Active Not RecruitingPhase 1/2

Gene Transfer Study in Patients With Late Onset Pompe Disease

NCT04174105 · Pompe Disease (Late-onset)

Active Not RecruitingEARLY Phase 1

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

NCT06109948 · Healthy, Late Onset Pompe Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 13, 2026Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment7

Start dateDec 2018

Last updatedApr 13, 2026

Condition

Locations shown

Duke University

Durham, North Carolina

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 13, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions